229 related articles for article (PubMed ID: 36856571)
1. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
[No Abstract] [Full Text] [Related]
2. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
[TBL] [Abstract][Full Text] [Related]
3. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
[TBL] [Abstract][Full Text] [Related]
4. Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs.
Tookes HE; Bartholomew TS; Suarez E; Ekowo E; Ginoza M; Forrest DW; Serota DP; Rodriguez A; Kolber MA; Feaster DJ; Mooss A; Boyd D; Sternberg C; Metsch LR
Drug Alcohol Depend; 2021 Dec; 229(Pt A):109124. PubMed ID: 34781096
[TBL] [Abstract][Full Text] [Related]
5. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE
Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183
[TBL] [Abstract][Full Text] [Related]
6. Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma.
Scaramutti C; Hervera B; Rivera Y; Chueng TA; Forrest DW; Suarez E; Serota DP; Alkamli H; Ciraldo K; Bartholomew TS; Tookes HE
Harm Reduct J; 2024 Feb; 21(1):50. PubMed ID: 38396017
[TBL] [Abstract][Full Text] [Related]
7. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
9. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
10. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
[TBL] [Abstract][Full Text] [Related]
11. Network centrality and HIV prevention service use among people who inject drugs: Findings from a sociometric network cohort in New Delhi, India.
Prata Menezes N; Mehta SH; Wesolowski A; Clipman SJ; Srikrishnan AK; Kumar MS; Zook KJC; Lucas GM; Latkin C; Solomon SS
Addiction; 2024 Mar; 119(3):570-581. PubMed ID: 37967827
[TBL] [Abstract][Full Text] [Related]
12. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts.
Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD
J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India.
Ganapathi L; McFall AM; Greco KF; Srikrishnan AK; Kumar MS; Mayer KH; O'Cleirigh C; Mehta SH; Lucas GM; Solomon SS
Drug Alcohol Depend; 2023 May; 246():109839. PubMed ID: 37031487
[TBL] [Abstract][Full Text] [Related]
14. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state.
Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM
Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523
[TBL] [Abstract][Full Text] [Related]
15. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
[TBL] [Abstract][Full Text] [Related]
16. Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study.
Shelby T; Zhou X; Barber D; Altice F
J Med Internet Res; 2021 Jul; 23(7):e25428. PubMed ID: 34259640
[TBL] [Abstract][Full Text] [Related]
17. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
[TBL] [Abstract][Full Text] [Related]
18. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
[TBL] [Abstract][Full Text] [Related]
19. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
20. Retention of people who inject drugs enrolled in a 'medications for opioid use disorder' (MOUD) programme in Uganda.
Mudiope P; Mutamba BB; Komuhangi L; Nangendo J; Alamo S; Mathers B; Makumbi F; Wanyenze R
Addict Sci Clin Pract; 2024 May; 19(1):39. PubMed ID: 38750568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
